九强生物(300406) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 reached ¥373,680,102.50, representing a 231.58% increase compared to ¥112,695,168.38 in the same period last year[8]. - Net profit attributable to shareholders was ¥112,160,261.95, a significant increase of 780.50% from ¥12,738,317.70 in the previous year[8]. - The basic earnings per share rose to ¥0.19, reflecting a 533.33% increase from ¥0.03 in the same period last year[8]. - The company's operating revenue for the reporting period reached 373.68 million yuan, a year-on-year increase of 231.58% from 112.70 million yuan, primarily due to the recovery from the COVID-19 pandemic and the acquisition of Mai Xin[29]. - The net profit attributable to the parent company's shareholders was 112.16 million yuan, up 780.50% compared to 12.74 million yuan in the same period last year[29]. - The company's total assets at the end of the reporting period were ¥4,044,781,776.41, up 2.05% from ¥3,963,667,036.44 at the end of the previous year[8]. - The weighted average return on equity for the reporting period was 3.45%, an increase from 0.64% in the previous year[8]. - The company's total liabilities decreased by 49.74% year-on-year, with short-term borrowings dropping from 1.16 million yuan to 0.58 million yuan[25]. - The tax expenses for the reporting period were 20.25 million yuan, a year-on-year increase of 676.21%, primarily due to increased income following the pandemic recovery[28]. Research and Development - The company increased its R&D investment to adapt to market demands and improve registration efficiency through active communication with regulatory authorities[17]. - The company's research and development expenses amounted to 25.61 million yuan, a year-on-year increase of 51.3%[28]. - The company has made significant progress in R&D, with multiple patents related to E. coli β-galactosidase receptor technology[32]. - In Q1 2021, the company obtained and applied for a total of 21 international and domestic patents[32]. - The company aims to enhance its product development and registration processes to align with market needs and regulatory trends[17]. Market and Competitive Landscape - The competitive landscape in the in vitro diagnostic industry is intensifying, with domestic manufacturers holding over 50% market share in biochemical diagnostics[12]. - The company faces risks related to new product development and registration, which can take 1-2 years to complete due to stringent regulatory requirements[15]. - The company is actively working to reduce the risk of dependence on imported raw materials by increasing investment in the development of domestic alternatives[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,286[18]. - The largest shareholder, China Pharmaceutical Investment Co., held 14.81% of shares, amounting to 87,209,302 shares[18]. - Liu Xi, a natural person, held 11.38% of shares, totaling 67,013,676 shares[18]. - Luo Aiping, another natural person, owned 10.34% of shares, which is 60,901,804 shares[18]. - The company has not conducted any repurchase agreements among the top 10 ordinary shareholders during the reporting period[22]. - The top 10 unrestricted ordinary shareholders collectively hold significant shares, with Zhou Xiaoyan holding 30,969,636 shares[22]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥18,666,833.49, but improved by 31.28% compared to -¥27,163,070.52 in the same period last year[8]. - Cash received from sales of goods and services was 284.21 million yuan, a 95.85% increase from 145.11 million yuan in the previous year, driven by revenue growth and the acquisition of Mai Xin[28]. - Cash flow from operating activities showed a net outflow of ¥18.67 million, an improvement from a net outflow of ¥27.16 million in the previous period[90]. - Cash and cash equivalents at the end of the period totaled ¥482.93 million, compared to ¥257.58 million at the end of the previous period, indicating an increase of approximately 87.2%[95]. - The ending cash and cash equivalents balance was $203,179,998.16, up from $181,128,464.97 in the previous period, showing an increase in liquidity[101]. Other Income and Expenses - The company reported a government subsidy of ¥2,271,809.31 during the reporting period, which is closely related to its business operations[8]. - The company recorded other income of 2.27 million yuan, a year-on-year increase of 119.75%, mainly due to increased government subsidies[25]. - The company incurred financial expenses of ¥2.21 million, significantly higher than ¥0.49 million in the previous period, representing an increase of approximately 353.5%[84]. - Sales expenses rose to ¥23.97 million from ¥19.77 million, reflecting an increase of about 21.1%[84].